Clinical trial
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate…
NCT00404612 · Lux Biosciences, Inc., Industry · Completed
Key facts
| NCT number | NCT00404612 |
|---|---|
| Title | A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis |
| Official title | A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis |
| Acronym | LUMINATE |
| Lead sponsor | Lux Biosciences, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Uveitis, Posterior, Intermediate, Panuveitis |
| Intervention type | Drug |
| Interventions | Placebo, LX211 |
| Enrollment | 218 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Nov 29, 2006 |
| Last update posted | Oct 11, 2012 |
| Countries | Austria, Canada, France, Germany, India, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: